Elicio Therapeutics, Inc. (ELTX)
2.41
-0.09
(-3.60%)
USD |
NASDAQ |
Sep 04, 13:16
Elicio Therapeutics Research and Development Expense (Annual) : 24.70M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 24.70M |
| December 31, 2024 | 33.34M |
| December 31, 2023 | 22.68M |
| December 31, 2022 | 17.05M |
| December 31, 2021 | 48.61M |
| Date | Value |
|---|---|
| December 31, 2020 | 38.88M |
| December 31, 2019 | 29.79M |
| December 31, 2018 | 9.151M |
| December 31, 2013 | 0.196M |
| December 31, 2012 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Precigen, Inc. | 40.06M |
| Agenus, Inc. | 79.34M |
| Amgen, Inc. | 6.974B |
| Anika Therapeutics, Inc. | 25.77M |
| BioCryst Pharmaceuticals, Inc. | 164.74M |